ScholarLink (思领科)
错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy

  • 期刊论文

  • 发表日期：

    2024年2月14日

查看全文
  • Masaki Shiota,
  • Dai Takamatsu,
  • Yoshiyuki Matsui,
  • Akira Yokomizo,
  • Shuichi Morizane,
  • Ryoichi Saito,
  • Makito Miyake,
  • Masakazu Tsutsumi,
  • Yoshiyuki Yamamoto,
  • Kojiro Tashiro,
  • Ryotaro Tomida,
  • Shintaro Narita,
  • Kohei Edamura,
  • Takahiro Yamaguchi,
  • Kohei Hashimoto,
  • Masashi Kato,
  • Takashi Kasahara,
  • Takayuki Yoshino,
  • Shusuke Akamatsu,
  • Tomoyuki Kaneko,
  • Akihiro Matsukawa,
  • Ryuji Matsumoto,
  • Akira Joraku,
  • Toshihiro Saito,
  • Takuma Kato,
  • Manabu Kato,
  • Hideki Enokida,
  • Shinichi Sakamoto,
  • Naoki Terada,
  • Hidenori Kanno,
  • Naotaka Nishiyama,
  • Takahiro Kimura,
  • Hiroshi Kitamura,
  • Masatoshi Eto

摘要

Background

This study aimed to create a prognostic model to predict disease recurrence among patients with lymph node involvement but no prostate-specific antigen (PSA) persistence and to explore its clinical utility.

Methods

The study analyzed patients with lymph node involvement after pelvic lymph node dissection with radical prostatectomy in whom no PSA persistence was observed between 2006 and 2019 at 33 institutions. Prognostic factors for recurrence-free survival (RFS) were analyzed by the Cox proportional hazards model.

Results

Among 231 patients, 127 experienced disease recurrence. The factors prognostic for RFS were PSA level at diagnosis (≥ 20 vs. < 20 ng/mL: hazard ratio [HR], 1.66; 95% confidence interval [CI], 1.09–2.52; P = 0.017), International Society of Urological Pathology grade group at radical prostatectomy (RP) specimen (group ≥ 4 vs. ≤ 3: HR, 1.63; 95% CI 1.12–2.37; P = 0.010), pathologic T-stage (pT3b/4 vs. pT2/3a: HR, 1.70; 95% CI 1.20–2.42; P = 0.0031), and surgical margin status (positive vs. negative: HR, 1.60; 95% CI 1.13–2.28; P = 0.0086). The prognostic model using four parameters were associated with RFS and metastasis-free survival.

Conclusion

The prognostic model in combination with postoperative PSA value and number of lymph nodes is clinically useful for discussing treatment choice with patients.